All In Biotech

Drug Trial Radar · NCT05320380

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia

Last checked: Nov 19, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 1, 2023

Primary completion

Sep 1, 2023

Study completion Sep 1, 2023

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
ImmunoGen, Inc.; National Cancer Institute (NCI)
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial finds the highest safe dose of IMGN632 that can be given with other chemotherapy without causing severe side effects, studies what kind of side effects IMGN632 may cause, and determines whether IMGN632 is a beneficial treatment for leukemia in children that has come back after treatment or is difficult to treat. IMGN632 is a monoclonal antibody linked to a chemotherapy drug. IMGN632 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD123 receptors, and delivers the chemotherapy drug to kill them. Giving IMGN632 with other chemotherapy may cause the leukemia to stop growing or to shrink for a period of time.

Conditions

  • Recurrent Acute Myeloid Leukemia
  • Recurrent B Acute Lymphoblastic Leukemia
  • Recurrent Mixed Phenotype Acute Leukemia
  • Recurrent T Acute Lymphoblastic Leukemia
  • Refractory Acute Myeloid Leukemia
  • Refractory B Acute Lymphoblastic Leukemia
  • Refractory Mixed Phenotype Acute Leukemia
  • Refractory T Acute Lymphoblastic Leukemia

Interventions

  • Anti-CD123 ADC IMGN632Drug

    Given IV

  • Bone Marrow Aspiration and BiopsyProcedure

    Undergo bone marrow aspiration/biopsy

  • CytarabineDrug

    Given IT and IV

  • Fludarabine PhosphateDrug

    Given IV

  • Hydrocortisone Sodium SuccinateDrug

    Given IT

  • Liposome-encapsulated Daunorubicin-CytarabineDrug

    Given IV

  • MethotrexateDrug

    Given IT

  • PrednisoloneDrug

    Given IT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase 2 dose (RP2D) of IMGN632 monotherapy (Cohort 1)Time frame: During cycle 1 (Each cycle = 42 days)
  2. Flow-based overall response rate (ORR) (Cohort 1)Time frame: During cycle 1 (Each cycle = 42 days)
  3. RP2D of combination therapy (Cohort 2)Time frame: During cycle 1 (Each cycle = 42 days)
  4. Minimal residual disease (MRD) negative flow-based ORR (Cohort 3)Time frame: Up to two cycles of IMGN632 with chemotherapy (Each cycle = 42 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.